Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength [Yahoo! Finance]
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: Yahoo! Finance
See our latest analysis for Rapport Therapeutics. With the share price at US$30.12, the strong 1 day share price return of 8.89% sits against a modest 90 day share price return of 12.64% and an 80.47% total shareholder return over the past year. This suggests momentum has been building over a longer stretch, even if shorter term moves have been mixed. If Rapport's recent swing has you looking beyond a single name, this is a good moment to scan other healthcare opportunities through our healthcare stocks With Rapport still loss making, trading at US$30.12 and sitting well below an average analyst price target of US$52.25, you have to ask: is this an underappreciated CNS pipeline, or is the market already pricing in future growth? On a P/B of 2.8x at a share price of US$30.12, Rapport looks cheaper than its closest peers but slightly richer than the broader US pharmaceuticals group. The P/B ratio compares a company's market value with its book value, which is essentially net
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics (NASDAQ:RAPP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the PipelineGlobeNewswire
- Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]Yahoo! Finance
- Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
RAPP
Earnings
- 11/6/25 - Beat
RAPP
Sec Filings
- 1/7/26 - Form 8-K
- 1/7/26 - Form 424B5
- 1/7/26 - Form 8-K
- RAPP's page on the SEC website